Insmed(INSM)
Focus: Insmed is a public biotechnology company specializing in inhalable liposomal therapeutics across neurology, rare diseases, cardiovascular, respiratory, and ophthalmology. With 1-50 employees and $305M in FY2025 revenue, it operates as a lean, focused biotech with significant R&D investment.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
86+8 this month
Growing — net +8 jobs in 30d
28 jobs added vs 20 removed. Steady team buildout.
Should You Work at Insmed?
AI assessmentInsmed offers meaningful impact in specialty respiratory/rare disease innovation with solid financial footing, but steep R&D burn and small scale require comfort with focused expertise and limited internal career paths.
Why Work Here
- Leadership role in inhalable liposomal drug delivery with clear market traction: ARIKAYCE KIT at peak lifecycle through 2035 and BRINSUPRI recently launched
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$305M
Key Products
Declining
LOE Approaching
BLA-approved product approaching loss of exclusivity with no specified indication; likely mature revenue contributor at risk.
Help build intelligence for Insmed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.